Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials

DOI: 10.21037/cdt.2017.08.16

Keywords: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is), dyslipidemia, coronary artery disease, atherosclerosis, meta-analysis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text